The USF Health Parkinson’s Disease and Movement Disorders Center is recognized as a National Parkinson Foundation Center of Excellence. As this region’s primary Parkinson’s center, we provide cutting-edge care to patients with Parkinson’s disease, a Parkinson Study Group, and an NIH Neuroprotective Exploratory Trials (NET-PD) site, in which our multi-disciplinary team is developing medications to slow or stop the progression of Parkinson’s disease.
Our facilities also include a Parkinson’s Disease and Balance Center, where patients receive specialized care for their parkinsonism's and balance disorders, including atypical parkinsonism's, such as progressive supranuclear palsy and multiple system atrophy. We also work extensively with patients with other movement disorders, including essential tremor, ataxia and dystonia. Other treatment options including physical therapy, occupational therapy, speech therapy, exercise, and nutrition are emphasized. Special attention is paid to the neuropsychiatric needs of movement disorders patients as well. The center also collaborates closely with neurosurgery in treating patients who require deep brain stimulation for Parkinson's disease and tremor.
As an academic medical center, the USF Health Parkinson’s Disease and Movement Disorders Center is at the forefront in developing new medical and surgical treatment options. We are an international leader in the advancing of Parkinson’s disease management, and we utilize this new knowledge to improve both diagnosis and patient care.
The USF Health Parkinson’s Disease and Movement Disorders Center is committed to advancing treatments and improving the quality of life for individuals living with Parkinson's disease and other movement disorders. Please take a moment to complete our survey if you are interested in learning more about research opportunities and how you can make an impact:
To schedule an appointment or contact our office, please contact us at:
Phone: (813) 821-9135
Fax: (813) 821-9758
USF Health Byrd Institute (6th Floor)
4001 E. Fletcher Avenue
Tampa, FL 33613
Learn more about Parkinson’s Disease and latest advancements of our center on social media:
Instagram - @usfparkinsonscenter
Facebook - USF Parkinson’s Disease and Movement Disorder Center
LinkedIn - USF Parkinson's Disease and Movement Disorders Center
Brief Summary: This study will examine the potential of CVN424 to improve motor and non-motor functions in individuals with early untreated Parkinson’s Disease (PD).
Status: Recruiting - For more information, review the study record:
https://clinicaltrials.gov/study/NCT06006247?spons=Cerevance&rank=2
Brief summary:
The purpose of this study is to assess the effect of tavapadon on the change from baseline in total daily hours of "on" time without troublesome dyskinesia in L-Dopa-treated participants with Parkinson's Disease (PD) who are experiencing motor fluctuations.
Status:
Recruiting - For more information, review the study record:
https://clinicaltrials.gov/study/NCT04542499?term=robert%20hauser&rank=1
Description:
A Study to Assess the Safety of BIIB122 Tablets and if it Can Flow the Worsening of Early-Stage Parkinson’s Disease in participants between the Ages of 30 and 80 (LUMA)
Status:
Recruiting - For more information, review the study record:
https://clinicaltrials.gov/study/NCT05348785?term=robert%20hauser&rank=7
Brief summary:
The purpose of this study is to evaluate the clinical efficacy, safety and pharmacokinetics (PK) of 2 fixed doses of tavapadon and placebo in participants with early PD.
Status:
Recruiting - For more information, review the study record:
https://clinicaltrials.gov/study/NCT04201093?term=robert%20hauser&rank=8
Brief summary:
The Parkinson Progression Marker Initiative (PPMI) is a longitudinal, observational, multi-center natural history study to assess progression of clinical features, digital outcomes, and imaging, biologic and genetic markers of Parkinson's disease (PD) progression in study participants with manifest PD, prodromal PD, and healthy controls.
The overall goal of PPMI is to identify markers of disease progression for use in clinical trials of therapies to reduce progression of PD disability.
Status:
Recruiting - For more information, review the study record:
https://clinicaltrials.gov/study/NCT04477785?term=robert%20hauser&rank=9
Brief summary:
A Study to Assess the Safety and Efficacy of JZP385 in the Treatment of Adults with Moderate to Severe Essential Tremor (ET)
Status:
Recruiting - For more information, review the study record:
https://clinicaltrials.gov/study/NCT05122650?term=jzp385-201&rank=1
Brief summary:
A study of suvecaltamide in adults with moderate to severe residual tremor in Parkinson’s Disease
Status:
Recruiting - For more information, review the study record:
https://clinicaltrials.gov/study/NCT05642442?term=jzp385-202&rank=1
Brief summary:
This is a double-blinded, controlled, randomized clinical trial (RCT) to establish the safety and efficacy of a non-invasive neuromodulation device for treating symptoms associated with Parkinson's disease.
Status:
Recruiting - For more information, review the study record:
https://clinicaltrials.gov/study/NCT04797611?term=SNS-PD-002&rank=1&limit=10
Brief summary:
This study investigates the safety and tolerability of drug IkT-148009 in untreated Parkinson's disease volunteers (30 to 80 years old). It also looks at the pharmacokinetics of IkT-148009 in the body and evaluates the effect of IkT-148009 on motor and non-motor features of the disease.
Status:
Recruiting - For more information, review the study record:
https://www.clinicaltrials.gov/study/NCT05424276?spons=Inhibikase%20Therapeutics,%20Inc.&rank=2
For more information or to enroll in our clinical trials, contact:
Erica Botting
ericabotting@usf.edu
(813) 974-8026
Robert Hauser, MD, MBA
Natalya Shneyder, MD
Kelly Hussey, MPAS, PA-C
Jennifer Koebert, MPAS, MPH, PA-C